Progressive multifocal leukoencephalopathy in a multiple Sclerosis patient diagnosed after switching from natalizumab to fingolimod by Sinnecker, T. et al.
Case Report
Progressive Multifocal Leukoencephalopathy in
a Multiple Sclerosis Patient Diagnosed after Switching from
Natalizumab to Fingolimod
Tim Sinnecker,1,2,3 Jalal Othman,1 Marc Kühl,1 Imke Metz,4 Thoralf Niendorf,5,6
Annett Kunkel,1 Friedemann Paul,2,6,7,8 Jens Wuerfel,2,9 and Juergen Faiss1
1Department of Neurology, Asklepios Fachklinikum Teupitz, Teupitz, Germany
2NeuroCure Clinical Research Center, Charite´-Universita¨tsmedizin Berlin, Berlin, Germany
3Department of Neurology, Universita¨tsspital Basel, Basel, Switzerland
4Department of Neuropathology, Universita¨tsmedizin Go¨ttingen, Go¨ttingen, Germany
5Berlin Ultrahigh Field Facility, Max Delbru¨ck Center for Molecular Medicine, Berlin, Germany
6Experimental and Clinical Research Center, Charite´-Universita¨tsmedizin Berlin and Max Delbru¨ck Center for Molecular Medicine,
Berlin, Germany
7Clinical and Experimental Multiple Sclerosis Research Center, Charite´-Universita¨tsmedizin Berlin, Berlin, Germany
8Department of Neurology, Charite´-Universita¨tsmedizin Berlin, Berlin, Germany
9Medical Imaging Analysis Center AG, Basel, Switzerland
Correspondence should be addressed to Friedemann Paul; friedemann.paul@charite.de
Received 1 June 2016; Revised 21 August 2016; Accepted 12 October 2016
Academic Editor: Dominic B. Fee
Copyright © 2016 Tim Sinnecker et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Natalizumab- (NTZ-) associated progressive multifocal leukoencephalopathy (PML) is a severe and often disabling
infectious central nervous system disease that can become evident in multiple sclerosis (MS) patients after NTZ discontinuation.
Recently, novel diagnostic biomarkers for the assessment of PML risk in NTZ treated MS patients such as the anti-JC virus
antibody index have been reported, and the clinical relevance of milky-way lesions detectable by MRI has been discussed. Case
Presentation and Conclusion. We report a MS patient in whom PML was highly suspected solely based on MRI findings after
switching from NTZ to fingolimod despite repeatedly negative (ultrasensitive) polymerase chain reaction (PCR) testing for JC
virus DNA in cerebrospinal fluid. The PML diagnosis was histopathologically confirmed by brain biopsy. The occurrence of an
immune reconstitution inflammatory syndrome (IRIS) during fingolimod therapy, elevated measures of JCV antibody indices, and
the relevance of milky-way-like lesions detectable by (7 T) MRI are discussed.
1. Introduction
Progressive multifocal leukoencephalopathy (PML) is an
opportunistic infection of the central nervous system (CNS)
caused by JC polyomavirus (JCV) targeting oligodendrocytes
and astrocytes and leading to oligodendrocyte death [1].
Symptoms are greatly variable, depending on the localisation
of the infection in the brain [2]. Clinically, patients present
with behavioural abnormalities, cognitive impairment, focal
neurological deficits, and/or epileptic seizures. The course of
the disease is often fatal or rendering the patient severely
disabled [2].
PML is observed in patients with a marked immuno-
suppression, for instance, due to an infection with HIV or
as a result of an immunosuppressive therapy after organ
transplantation. It may also occur in multiple sclerosis (MS)
patients treated with natalizumab (NTZ). NTZ is a mono-
clonal antibody directed against 𝛼4-integrin that hinders the
transmigration of white blood cells through the blood vessel
wall into the CNS. Risk factors of NTZ-associated PML are
duration of therapy with NTZ (with amarked increase in risk
after two years), use of immunosuppressants before initiation
of NTZ therapy, and a positive anti-JC virus antibody status
[3–7].
Hindawi Publishing Corporation
Case Reports in Neurological Medicine
Volume 2016, Article ID 5876798, 8 pages
http://dx.doi.org/10.1155/2016/5876798
2 Case Reports in Neurological Medicine
Jan 15 Feb Mar MayApr June July Jan 16Timeline
Tr
ea
tm
en
t
Discontinuation 
of NTZ
Discontinuation of 
fingolimod and plasma
exchange (5 cycles)
Negative PCR for JCV DNA in CSF
Negative PCR for JCV DNA in CSF; JCV-ASI 7.3
Negative PCR for JCV DNA
in CSF; JCV-ASI 10.3
Discontinuation of 
fingolimod;
plasma exchange (5 
cycles)
1094 copies of JCV
JC
V
D
N
A
M
RI
M
RI
T1
w
 G
A
D
Apr 10/13, 2015 Apr 21, 2015 May 22, 2015 June 11, 2015 July 13, 2015 Jan 26, 2015
FL
A
IR
Fingolimod 0.5mg/d
Fingolimod 0.5mg/d
mirtazapine 30mg/d;
DNA/10𝜇L biopsy extract
1.5T1.5T1.5T1.5T1.5T1.5T
7T7T
Figure 1:Overview. Survey of treatment decisions and laboratory andMRI findings of the patient under discussion. In detail, 1.5 TT1weighted
Gadolinium enhanced (T1W GAD) and 1.5 T fluid attenuated inversion recovery (FLAIR) images are presented.
After clinical suspicion of PML, diagnosis is established
by magnetic resonance imaging (MRI) findings and PCR
detection of JCV DNA in the cerebrospinal fluid (CSF) [8].
In rare cases, a brain biopsy has to be performed to diagnose
PML [8].
Apart from reestablishing a competent immune response,
there is no PML-specific therapy with proven efficacy [9].
In MS patients with NTZ-associated PML, plasma exchange
(PLEX) or immunoadsorption (IA) is performed to accel-
erate NTZ clearance [10]. However, immune reconstitution
inflammatory syndrome (IRIS), a condition characterized
by an overwhelming inflammatory response during immune
reconstitution, can develop or deteriorate during PLEX lead-
ing to clinical worsening [11].
In vitro studies postulate an infection via the serotonin
receptor 5HT2a [12]. Hence, serotonin reuptake inhibitors
like mirtazapine are frequently prescribed. However, along
with other experimental therapeutic strategies including
mefloquine or amantadine, clinical confirmation is still miss-
ing [13].
Here, we report an MS case in which PML-IRIS was
diagnosed after switching from NTZ to fingolimod. Brain
biopsy and advanced neuroimaging findings including ultra-
high field MRI at 7 Tesla (T) are presented.
2. Case Presentation
A 48-year-old woman with relapsing-remitting MS (RRMS)
was switched after 6 months of treatment with interferon-1b
to NTZ in May 2008 due to ongoing clinical and paraclinical
disease activity including multiple Gadolinium enhancing
brain lesions detected with MRI.
At that point, the Expanded Disability Status Scale Score
(EDSS) was 5.5.
We did not observe any evidence of clinical or MRI
disease activity during NTZ treatment, and the EDSS subse-
quently decreased to 2.5.
Figure 1 chronologically summarizes all paraclinical find-
ings including MRI results and treatment decisions.
In January 2015, NTZ was discontinued after a total
of 86 infusions on the background of seroconversion to
positive JCV serum antibodies (STRATIFY, Unilabs, Geneva,
Switzerland), indicating an increased PML risk. Anti-JCV
antibody index was not available at that time.
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Figure 2: Signs of IRIS at the time of PML diagnosis. 1.5 T
T1w Gadolinium enhanced MR images are presented. Extensive
Gadolinium enhancement suggestive of IRIS (black arrows) was
observed at the edge of confluent PML lesions.
After a wash-out period of 2 months, fingolimod was
started on the 18th of March 2015. Previous brain MRI
(February 2015) did not show any signs of PML.
Three weeks later (10th April 2015), routine brain MRI
at 1.5 T revealed PML-suspicious bifrontal confluent lesions
with (sub)cortical involvement. Moreover, multiple milky-
way-like Gadolinium enhancing and T2 weighted (T2w)
hyperintense punctate lesions were detected by MRI in these
areas (Figure 1). In addition, perilesional contrast enhance-
ment around confluent PML-suspicious lesions suggestive of
IRIS was detectable (Figure 2). Diffusion weighted MRI did
not show intralesional hyperdiffusivity nor signs of restricted
diffusion at the edge of the lesions (Figure 3); both of which
are considered to be typical of PML [14].
We did not observe any signs of clinical worsening, the
polymerase chain reaction (PCR) testing for JCVDNA inCSF
(Institute for Virology, Heinrich Heine University, Du¨sseldorf,
Germany) was negative, and the lymphocyte count was only
slightly decreased (0.91 G/L, reference range 1–4G/L).
Fingolimod was immediately discontinued, and the
patient underwent five cycles of plasma exchange. Ultrahigh
field MRI at 7 Tesla was performed five days after discontin-
uation of fingolimod confirming initial 1.5 TMRI findings by
detailing confluent PML-suspicious lesionswith (sub)cortical
involvement (Figure 4) and by delineating numerous punc-
tate Gadolinium enhancing lesions (Figure 5, circles) on top
of MS-suspicious ring-enhancing lesions (Figure 5, white
arrows).
1.5 T MRI performed immediately after PLEX did not
show any signs of PML progression (Figure 1), and PCR did
again not reveal JCV DNA in CSF. Thus, fingolimod was
reinitiated on 22th of April 2015 to prevent possible rebound
effects after discontinuation of NTZ, andmonthlyMRIs were
performed.
One month later (22th of May 2015) a control MRI at
1.5 T showed slightly enlarging FLAIR hyperintense lesions
(Figure 1). Clinically, we observed a latent right-sided bra-
chiofacial paresis and a slightly increased irritability reported
by her daughter at that time; EDSS 3.0. PCR testing for JCV
DNA inCSFwas repeatedly negative, but JCV antibody index
(JCV-ASI) was markedly increased (10.3). Retrospectively,
JCV-ASI was already elevated at the time of the second CSF
analysis (JCV-ASI 7.3).
As a consequence, fingolimod was again discontinued,
mirtazapine 30mg/d orally was started, and another cycle
of plasma exchange was carried out. Neuropsychological
examinations and electroencephalography (EEG) did not
reveal any changes.
On 24th of July 2015, a stereotactic biopsy was carried
out since an ultrasensitive PCR of JCV DNA (Laboratory
of Molecular Medicine and Neuroscience, National Institute
of Health, Bethesda, USA) repetitively failed to detect JCV
DNA in CSF. The biopsy showed demyelinating lesions with
a prominent CD8 dominated inflammatory infiltrate with
numerous plasma cells (Figure 6). Although neuropatholog-
ical findings were highly suggestive of IRIS in the context of
PML, SV40-positive cells (JCV-infected cells) could not be
detected (Institute of Neuropathology, University of Go¨ttingen,
Germany). JCV multiplex quantitative real-time PCR assay
(JC Multiplex qPCR) of paraffin embedded brain tissue was
initiated and revealed 1094 viral copies per 10 𝜇L extract,
consistent with a variant most commonly associated with
PML (Laboratory of Molecular Medicine and Neuroscience,
National Institute of Health, Bethesda, USA) [14], finally
proving the PML diagnosis.
Mirtazapine was continued and glatiramer acetate treat-
ment initiated. The patient remained clinically stable, and
MRI (26th of January 2016) showed decreasing PML lesions
without any signs of Gadolinium enhancement (Figure 1,
EDSS 3.0).
3. Discussion
We report a case of subclinical simultaneous PML-IRIS that
was diagnosed after switching from NTZ to fingolimod.
Initially, PML was suspected exclusively on the basis of MRI
findings despite repeatedly negative (ultrasensitive) PCR
testing for JCV DNA in CSF. The diagnosis was further
complicated by the absence of PML-characteristic changes in
diffusivity as investigated by diffusion weightedMRI. Finally,
PML was confirmed via brain biopsy.
Alongwith other reports in the literature [15, 16], this case
thus underlines the need of additional sensitive biomarkers
for an earlier diagnosis of PML. In fact, PCR testing for
JCV DNA in CSF is limited in sensitivity even when using
ultrasensitive PCR assays that can detect up to 10 copies of
JCV DNA per milliliter CSF [8, 16]. Notwithstanding these
efforts, such highly sensitive assays are not broadly available,
and the clinical relevance of very low measures of JCV DNA
copies is still under discussion [17].
Recently, the JCV antibody index was introduced as a
novel biomarker that potentially can help to better distinguish
between NTZ-associated PML and non-PMLMS patients [4,
4 Case Reports in Neurological Medicine
DWI
(a)
ADC
(b)
DWI
(c)
ADC
(d)
Figure 3: No signs of abnormal diffusion. Diffusion weighted MRI at 1.5 T ((a) and (c)) did reveal neither signs of central hyperdiffusibility
(circles) nor signs of restricted diffusion (circles) at the edge of PML lesions (black arrows, (b) and (d)). Both of which were reported to be
characteristic for PML lesions.
16]. Indeed, the JCV antibody index was markedly increased
in our case and continued to rise during PML expansion.
Other PML cases of elevated JCV antibody indices despite
repeatedly negative PCR testing for JCV DNA in CSF have
been reported [15, 16].
Furthermore, the presented case also highlights the
importance of a stringent clinical and paraclinical follow-
up of MS patients before and after discontinuing NTZ since
PML(-IRIS) was previously described after NTZ discon-
tinuation [18] and while switching from NTZ to another
immunomodulatory therapy. As reported previously, IRIS
may even occur during fingolimod-associated lymphopenia
[19, 20]. Indeed, marginally decreased blood lymphocyte
counts and signs of IRIS were detectable at the time of first
PML-suspicious MRI lesions in our case.
In addition to this extensive laboratory and clinical
workup, we performed highly resolving ultrahigh field MRI
at 7 T. In general, 7 T MRI benefits from an increased signal-
to-noise ratio, a high spatial resolution, and enhanced sus-
ceptibility effects. Thus, 7 T MRI has improved the detection
and morphological characterization of neuroinflammatory
brain lesions [21–23]. Most importantly, a small venous vessel
is often detectable within the center of MS lesions by using
gradient echo MR techniques at 7 T [24–28], facilitating
the distinction to other CNS diseases such as neuromyelitis
optica [29, 30] and Susac syndrome [31].
Recently, 7 T MRI revealed contrast-enhancing milky-
way-like lesions that expanded intomore typical PML lesions
over time in a single case of simultaneous PML, IRIS, and an
ongoing MS disease activity [32]. In contrast to MS lesions,
a small central vessel was not commonly detectable within
these lesions [32].
In general, the mechanisms of contrast enhancement
in NTZ-associated PML are not fully understood. Contrast
enhancement is a correlate of blood-brain-barrier (BBB)
breakdown [11, 13, 33–35]. However, JCV-infected lympho-
cytes may also cross the intact BBB to infect oligodendro-
cytes [36, 37]. In other words, BBB breakdown is not a
prerequisite of PML development. In HIV, indeed, PML is
frequently characterized by little or no inflammatory signs
and absence of BBB breakdown [38]. Thus, patchy areas of
peripheral contrast enhancement at the edge of HIV-PML
lesions are commonly considered as a sign of IRIS but not
a PML imaging feature [38, 39]. Following this assumption,
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Figure 4: 7 T T2∗ weighted imaging in PML. A 7T T2∗ weighted (T2∗w) image with a spatial resolution of (0.2 × 0.2) mm is shown. Please
note the difference in lesion morphology between periventricular oval MS lesions that are centered on a small venous vessel (arrows) and
confluent PML lesions (circle) that also involve U-fibers and subcortical areas.
(a) (b)
Figure 5: Patterns of Gadolinium enhancement on 7 T VIBE images. A maximum intensity projection map of a 7 T T1 weighted Gadolinium
enhanced volumetric interpolated brain examination ((a), VIBE) and an exemplary VIBE image (b) are displayed. PML-suspicious punctate
Gadolinium enhancing lesions are clearly visible (circles). Ring-enhancing lesions (e.g., arrows) suggestive of MS lesions are delineated.
recent PML studies have interpreted any kind of contrast
enhancement in or around PML lesions as a sign of IRIS
[11]. However, it is not known whether this also holds true
for NTZ-associated PML, where the immune response is
present and thus different compared to HIV. In a recent
report, no histopathological features of IRIS were present in a
bioptical probe of NTZ-associated PML, despite perilesional
contrast enhancement on MRI. The authors concluded that,
up to date, IRIS remains a histopathological diagnosis [40]. In
our case, histopathology revealed prominent CD8 dominated
inflammatory infiltrates with numerous plasma cells highly
suggestive of IRIS, although clinical worsening, that usually
accompanies IRIS, was absent.
In addition to patchy contrast enhancement at the edges
of PML lesions, punctate contrast-enhancing lesions have
been described [35, 41–43]. The clinical relevance of such
small punctate lesion is, however, still a matter of discussion:
On the one hand, milky-way-like punctate lesions were
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Figure 6: Neuropathological findings. Histology revealed areas of focal demyelination as indicated by a loss of myelin basic protein (a) and
proteolipid protein (b). Despite the presence of prominent CD8 dominated inflammatory infiltrates (c), SV40-positive cells (JCV-infected
cells, (d)) could not be detected.
associated with an overwhelming immunoreaction, namely,
IRIS, against JCV [43]. Methylprednisolone pulse therapy
would be beneficial in such a situation. On the other hand, it
was hypothesized that these lesions represent areas of active
JCV replication that is probably adequately recognized by
the immune system [41]. In such a scenario, glucocorticoid
induced immunosuppressionmight be harmful. In alignment
with this hypothesis, we have previously described clinical
worsening and increasing JCVDNA copies in CSF in a NTZ-
PML case with punctate lesions during methylprednisolone
pulse therapy [32].
Interestingly, there are some differences in the clinical
presentation and MRI finding between the “current” PML
case presented here and the previous one [32]. In detail, we
observed fewer milky-way-like lesions and the expansion of
confluent lesions over time was more limited in the “current”
case. Of note, the “current” patient only received plasma
exchange, and she was not treated with methylprednisolone.
Which of all these factors has primarily influenced the
overall better clinical outcome of the presented patient
remains unknown, but it emphasizes the need of systematic
(ultra)high field MRI studies to address these questions.
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